Do analysts recommend KALA or ATYR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 aTyr Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is KALA or ATYR more profitable?

aTyr Pharma's return on equity of -95.89% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -222.35% -70.23% aTyr Pharma N/A -95.89% -69.67%

Does the media favor KALA or ATYR?

In the previous week, KALA BIO had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 3 mentions for KALA BIO and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.82 beat KALA BIO's score of 0.59 indicating that aTyr Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KALA BIO 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend KALA or QNCX?

Quince Therapeutics has a consensus target price of $189.88, indicating a potential upside of 493.17%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than KALA BIO. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quince Therapeutics 2 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.64

Which has better valuation and earnings, KALA or QNCX?

Quince Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$31.96 N/A Quince Therapeutics N/A N/A -$83.98M -$156.71 N/A

Is KALA or QNCX more profitable?

Quince Therapeutics' return on equity of 0.00% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -222.35% -70.23% Quince Therapeutics N/A N/A -133.84%

Does the media prefer KALA or QNCX?

In the previous week, Quince Therapeutics had 5 more articles in the media than KALA BIO. MarketBeat recorded 8 mentions for Quince Therapeutics and 3 mentions for KALA BIO. Quince Therapeutics' average media sentiment score of 0.65 beat KALA BIO's score of 0.59 indicating that Quince Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KALA BIO 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quince Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer KALA or ATOS?

Atossa Genetics has a consensus price target of $20.33, suggesting a potential upside of 750.77%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Atossa Genetics is more favorable than KALA BIO. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has preferable earnings & valuation, KALA or ATOS?

Atossa Genetics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$31.96 N/A Atossa Genetics N/A N/A -$34.77M -$3.11 N/A

Is KALA or ATOS more profitable?

Atossa Genetics' return on equity of -102.99% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -222.35% -70.23% Atossa Genetics N/A -102.99% -85.78%

Does the media prefer KALA or ATOS?

In the previous week, Atossa Genetics had 9 more articles in the media than KALA BIO. MarketBeat recorded 12 mentions for Atossa Genetics and 3 mentions for KALA BIO. Atossa Genetics' average media sentiment score of 0.82 beat KALA BIO's score of 0.59 indicating that Atossa Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KALA BIO 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend KALA or KYNB?

Kyntra Bio has a consensus price target of $37.25, suggesting a potential upside of 508.66%. Given Kyntra Bio's stronger consensus rating and higher possible upside, analysts clearly believe Kyntra Bio is more favorable than KALA BIO. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher earnings & valuation, KALA or KYNB?

Kyntra Bio has higher revenue and earnings than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$31.96 N/A Kyntra Bio $6.44M 3.85 $183.45M $45.30 0.14

Is KALA or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to KALA BIO's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -222.35% -70.23% Kyntra Bio 2,199.13% N/A -47.27%

Does the media prefer KALA or KYNB?

In the previous week, KALA BIO and KALA BIO both had 3 articles in the media. Kyntra Bio's average media sentiment score of 0.61 beat KALA BIO's score of 0.59 indicating that Kyntra Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KALA BIO 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NXTC or KALA?

NextCure presently has a consensus price target of $19.00, suggesting a potential upside of 186.14%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than KALA BIO. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 KALA BIO 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, NXTC or KALA?

NextCure is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NextCure N/A N/A -$55.84M -$8.70 N/A KALA BIO N/A N/A -$26.98M -$31.96 N/A

Is NXTC or KALA more profitable?

NextCure's return on equity of -154.62% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -154.62% -100.19% KALA BIO N/A -222.35% -70.23%

KALA BIO (KALA) Competitors

$0.28 -0.01 (-4.76%)

Closing price 10/12/2026 04:00 PM Eastern

Extended Trading

$0.28 +0.00 (+0.71%)

As of 10/12/2026 07:30 PM Eastern

Compare

KALA vs. ATYR, QNCX, ATOS, KYNB, and NXTC

Should you buy KALA BIO stock or one of its competitors? KALA BIO's main competitors and comparable companies include aTyr Pharma (ATYR), Quince Therapeutics (QNCX), Atossa Genetics (ATOS), Kyntra Bio (KYNB), and NextCure (NXTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does KALA BIO compare to aTyr Pharma?

KALA BIO (NASDAQ:KALA) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

KALA BIO has higher earnings, but lower revenue than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A
aTyr Pharma	$190K	110.89	-$74.12M	-$0.62	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
aTyr Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

aTyr Pharma's return on equity of -95.89% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-222.35%	-70.23%
aTyr Pharma	N/A	-95.89%	-69.67%

In the previous week, KALA BIO had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 3 mentions for KALA BIO and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.82 beat KALA BIO's score of 0.59 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KALA BIO	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
aTyr Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

KALA BIO has a beta of -2.4, meaning that its share price is 340% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 2.2% of KALA BIO shares are held by company insiders. Comparatively, 5.0% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

aTyr Pharma beats KALA BIO on 11 of the 14 factors compared between the two stocks.

How does KALA BIO compare to Quince Therapeutics?

KALA BIO (NASDAQ:KALA) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by insiders. Comparatively, 5.6% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Quince Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A

Quince Therapeutics' return on equity of 0.00% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-222.35%	-70.23%
Quince Therapeutics	N/A	N/A	-133.84%

Quince Therapeutics has a consensus target price of $189.88, indicating a potential upside of 493.17%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than KALA BIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quince Therapeutics	2 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.64

KALA BIO has a beta of -2.4, suggesting that its share price is 340% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

In the previous week, Quince Therapeutics had 5 more articles in the media than KALA BIO. MarketBeat recorded 8 mentions for Quince Therapeutics and 3 mentions for KALA BIO. Quince Therapeutics' average media sentiment score of 0.65 beat KALA BIO's score of 0.59 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KALA BIO	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quince Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Quince Therapeutics beats KALA BIO on 10 of the 14 factors compared between the two stocks.

How does KALA BIO compare to Atossa Genetics?

KALA BIO (NASDAQ:KALA) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

KALA BIO has a beta of -2.4, suggesting that its stock price is 340% less volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Atossa Genetics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A

Atossa Genetics' return on equity of -102.99% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-222.35%	-70.23%
Atossa Genetics	N/A	-102.99%	-85.78%

24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Atossa Genetics had 9 more articles in the media than KALA BIO. MarketBeat recorded 12 mentions for Atossa Genetics and 3 mentions for KALA BIO. Atossa Genetics' average media sentiment score of 0.82 beat KALA BIO's score of 0.59 indicating that Atossa Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KALA BIO	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atossa Genetics has a consensus price target of $20.33, suggesting a potential upside of 750.77%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Atossa Genetics is more favorable than KALA BIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Atossa Genetics beats KALA BIO on 9 of the 13 factors compared between the two stocks.

How does KALA BIO compare to Kyntra Bio?

KALA BIO (NASDAQ:KALA) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 2.2% of KALA BIO shares are held by company insiders. Comparatively, 4.2% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

KALA BIO has a beta of -2.4, meaning that its stock price is 340% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Kyntra Bio has higher revenue and earnings than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A
Kyntra Bio	$6.44M	3.85	$183.45M	$45.30	0.14

Kyntra Bio has a net margin of 2,199.13% compared to KALA BIO's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-222.35%	-70.23%
Kyntra Bio	2,199.13%	N/A	-47.27%

In the previous week, KALA BIO and KALA BIO both had 3 articles in the media. Kyntra Bio's average media sentiment score of 0.61 beat KALA BIO's score of 0.59 indicating that Kyntra Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KALA BIO	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyntra Bio has a consensus price target of $37.25, suggesting a potential upside of 508.66%. Given Kyntra Bio's stronger consensus rating and higher possible upside, analysts clearly believe Kyntra Bio is more favorable than KALA BIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Kyntra Bio beats KALA BIO on 14 of the 14 factors compared between the two stocks.

How does KALA BIO compare to NextCure?

NextCure (NASDAQ:NXTC) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

NextCure has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.4, indicating that its share price is 340% less volatile than the broader market.

NextCure is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A
KALA BIO	N/A	N/A	-$26.98M	-$31.96	N/A

NextCure presently has a consensus price target of $19.00, suggesting a potential upside of 186.14%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than KALA BIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
KALA BIO	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NextCure's return on equity of -154.62% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-154.62%	-100.19%
KALA BIO	N/A	-222.35%	-70.23%

In the previous week, KALA BIO had 1 more articles in the media than NextCure. MarketBeat recorded 3 mentions for KALA BIO and 2 mentions for NextCure. KALA BIO's average media sentiment score of 0.59 beat NextCure's score of 0.27 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Overall Sentiment
NextCure	Neutral
KALA BIO	Positive

42.7% of NextCure shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 11.9% of NextCure shares are held by company insiders. Comparatively, 2.2% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

NextCure beats KALA BIO on 8 of the 13 factors compared between the two stocks.

Get KALA BIO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KALA vs. The Competition

Export

Metric	KALA BIO	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.68M	$3.94B	$7.27B	$13.27B
Dividend Yield	N/A	3.64%	2.52%	20.73%
P/E Ratio	-0.01	13.38	275.37	25.82
Price / Sales	N/A	1,216.33	581.95	91.82
Price / Cash	N/A	39.46	27.30	36.12
Price / Book	0.02	17.35	10.85	6.10
Net Income	-$26.98M	-$22.69M	$3.50B	$380.59M
7 Day Performance	-23.08%	-1.77%	-1.29%	-2.03%
1 Month Performance	-51.08%	-9.38%	-4.88%	-4.22%
1 Year Performance	-99.62%	12.88%	5.67%	-1.55%

KALA BIO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KALA KALA BIO	0.3811 of 5 stars	$0.28 -4.8%	N/A	-99.6%	$5.68M	N/A	N/A	6	Short Interest Increase Gap Down
ATYR aTyr Pharma	1.159 of 5 stars	$0.28 -1.8%	N/A	-79.7%	$27.80M	$190K	N/A	58
QNCX Quince Therapeutics	2.7713 of 5 stars	$26.72 -0.3%	$206.71 +673.6%	-91.4%	$27.27M	N/A	N/A	38	Gap Down
ATOS Atossa Genetics	2.2066 of 5 stars	$2.46 +0.4%	$20.33 +726.6%	-85.2%	$24.45M	N/A	N/A	14	News Coverage
KYNB Kyntra Bio	3.7875 of 5 stars	$6.13 +2.9%	$37.25 +507.7%	N/A	$24.13M	$6.44M	0.14	570

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KALA) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

KALA BIO (KALA) Competitors

KALA vs. ATYR, QNCX, ATOS, KYNB, and NXTC

How does KALA BIO compare to aTyr Pharma?

Summary

How does KALA BIO compare to Quince Therapeutics?

Summary

How does KALA BIO compare to Atossa Genetics?

Summary

How does KALA BIO compare to Kyntra Bio?

Summary

How does KALA BIO compare to NextCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA vs. The Competition

KALA BIO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

KALA BIO (KALA) Competitors

KALA vs. ATYR, QNCX, ATOS, KYNB, and NXTC

How does KALA BIO compare to aTyr Pharma?

Which has better earnings & valuation, KALA or ATYR?

Do analysts recommend KALA or ATYR?

Is KALA or ATYR more profitable?

Does the media favor KALA or ATYR?

Which has more volatility and risk, KALA or ATYR?

Do insiders and institutionals have more ownership in KALA or ATYR?

Summary

How does KALA BIO compare to Quince Therapeutics?

Do institutionals and insiders have more ownership in KALA or QNCX?

Which has better valuation and earnings, KALA or QNCX?

Is KALA or QNCX more profitable?

Do analysts recommend KALA or QNCX?

Which has more risk and volatility, KALA or QNCX?

Does the media prefer KALA or QNCX?

Summary

How does KALA BIO compare to Atossa Genetics?

Which has more volatility and risk, KALA or ATOS?

Which has preferable earnings & valuation, KALA or ATOS?

Is KALA or ATOS more profitable?

Do institutionals & insiders hold more shares of KALA or ATOS?

Does the media prefer KALA or ATOS?

Do analysts prefer KALA or ATOS?

Summary

How does KALA BIO compare to Kyntra Bio?

Do insiders & institutionals believe in KALA or KYNB?

Which has more risk and volatility, KALA or KYNB?

Which has higher earnings & valuation, KALA or KYNB?

Is KALA or KYNB more profitable?

Does the media prefer KALA or KYNB?

Do analysts recommend KALA or KYNB?

Summary

How does KALA BIO compare to NextCure?

Which has more risk & volatility, NXTC or KALA?

Which has preferable valuation and earnings, NXTC or KALA?

Do analysts recommend NXTC or KALA?

Is NXTC or KALA more profitable?

Does the media favor NXTC or KALA?

Do institutionals & insiders hold more shares of NXTC or KALA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA vs. The Competition

KALA BIO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools